Glenmark Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	163,472	133,217	118,131	115,832	123,049	109,439
Other Revenue	1,625	415.54	8,323	723.29	-	-
Revenue	165,097	133,633	126,454	116,556	123,049	109,439
Revenue Growth (YoY)	18.26%	5.68%	8.49%	-5.28%	12.44%	2.69%
Cost of Revenue	48,358	45,250	45,789	44,108	45,481	38,470
Gross Profit	116,739	88,383	80,665	72,448	77,568	70,970
Selling, General & Admin	40,863	36,814	34,465	31,833	29,176	28,103
Other Operating Expenses	31,751	27,639	25,924	23,541	25,124	21,271
Operating Expenses	78,123	69,314	66,208	61,066	59,168	53,809
Operating Income	38,616	19,069	14,457	11,382	18,400	17,160
Interest Expense	-2,328	-2,071	-5,160	-3,490	-2,981	-3,531
Interest & Investment Income	439.41	439.41	61.78	73.52	97.85	29.97
Currency Exchange Gain (Loss)	282.27	282.27	-	2,035	880.54	-752.09
Other Non Operating Income (Expenses)	1,695	-	-	-	688.35	468.65
EBT Excluding Unusual Items	38,705	17,720	9,359	10,000	17,086	13,376
Gain (Loss) on Sale of Assets	-	-	15.3	57.25	-64.64	3.54
Legal Settlements	-	-	-	-8,011	-	-
Other Unusual Items	-22,655	-3,728	-9,010	351.99	-2,609	445.45
Pretax Income	16,050	13,992	364.95	2,398	14,412	13,825
Income Tax Expense	5,399	3,521	18,673	3,294	4,476	4,124
Earnings From Continuing Operations	10,650	10,471	-18,309	-895.61	9,936	9,701
Earnings From Discontinued Operations	-	-	3,973	4,670	-	-
Net Income to Company	10,650	10,471	-14,335	3,774	9,936	9,701
Minority Interest in Earnings	0.7	-0.45	-681.46	-801.55	-519.38	-0.5
Net Income	10,651	10,471	-15,017	2,972	9,417	9,700
Net Income to Common	10,651	10,471	-15,017	2,972	9,417	9,700
Net Income Growth	-	-	-	-68.44%	-2.92%	25.01%
Shares Outstanding (Basic)	282	282	282	282	282	282
Shares Outstanding (Diluted)	282	282	282	282	282	282
Shares Change (YoY)	0.04%	0.01%	0.00%	-	-	-
EPS (Basic)	37.75	37.11	-53.22	10.53	33.37	34.38
EPS (Diluted)	37.74	37.11	-53.22	10.53	33.37	34.38
EPS Growth	-	-	-	-68.43%	-2.93%	25.01%
Free Cash Flow	-	-15,772	-11,638	176.29	3,185	3,565
Free Cash Flow Per Share	-	-55.89	-41.24	0.63	11.29	12.63
Dividend Per Share	-	2.500	2.500	2.500	2.500	2.500
Gross Margin	70.71%	66.14%	63.79%	62.16%	63.04%	64.85%
Operating Margin	23.39%	14.27%	11.43%	9.77%	14.95%	15.68%
Profit Margin	6.45%	7.84%	-11.88%	2.55%	7.65%	8.86%
Free Cash Flow Margin	-	-11.80%	-9.20%	0.15%	2.59%	3.26%
EBITDA	40,298	21,676	18,297	14,289	19,124	19,448
EBITDA Margin	24.41%	16.22%	14.47%	12.26%	15.54%	17.77%
D&A For EBITDA	1,682	2,607	3,840	2,907	723.93	2,287
EBIT	38,616	19,069	14,457	11,382	18,400	17,160
EBIT Margin	23.39%	14.27%	11.43%	9.77%	14.95%	15.68%
Effective Tax Rate	33.64%	25.16%	5116.72%	137.34%	31.06%	29.83%
Revenue as Reported	167,514	134,355	126,531	118,721	124,716	109,941
Advertising Expenses	-	6,079	5,157	5,270	4,349	4,287

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.